

Marc Talló, CSO – NoctuRNA tX

Marc Talló-Parra is the Chief Scientific Officer and co-founder of noctuRNA Therapeutics, a spin-off from Universitat Pompeu Fabra (UPF) focused on developing innovative therapies for infectious and non-infectious diseases using circular RNAs (circRNAs). Marc holds a PhD in Biomedicine from UPF, where his research focused on uncovering the role of circRNAs in viral infections, laying the scientific foundation for noctuRNA. In addition to his role at noctuRNA, Marc is an Associate Professor at Universitat Pompeu Fabra, where he contributes to both teaching and research in the field of RNA biology and viruses. He is a co-inventor on three patents and has received multiple recognitions, including the Technology Transfer Award and the Extraordinary Doctoral Thesis Award from UPF. Since 2024, Marc has led the scientific strategy at noctuRNA, driving the company's mission to harness the therapeutic potential of circRNAs.